Epirus Biopharmaceuticals (NASDAQ: EPRS) and Aevi Genomic Medicine (NASDAQ:GNMX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Earnings and Valuation

This table compares Epirus Biopharmaceuticals and Aevi Genomic Medicine’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Epirus Biopharmaceuticals N/A N/A N/A ($2.53) -0.06
Aevi Genomic Medicine N/A N/A -$37.80 million ($1.02) -1.25

Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Epirus Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Epirus Biopharmaceuticals has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Profitability

This table compares Epirus Biopharmaceuticals and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epirus Biopharmaceuticals -2,025.65% -208.66% -97.67%
Aevi Genomic Medicine N/A -125.94% -106.93%

Institutional and Insider Ownership

21.0% of Aevi Genomic Medicine shares are owned by institutional investors. 24.8% of Aevi Genomic Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Epirus Biopharmaceuticals and Aevi Genomic Medicine, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epirus Biopharmaceuticals 0 0 0 0 N/A
Aevi Genomic Medicine 0 1 1 0 2.50

Aevi Genomic Medicine has a consensus price target of $4.25, indicating a potential upside of 234.65%. Given Aevi Genomic Medicine’s higher probable upside, analysts clearly believe Aevi Genomic Medicine is more favorable than Epirus Biopharmaceuticals.

Summary

Aevi Genomic Medicine beats Epirus Biopharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Epirus Biopharmaceuticals

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Stock Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.